BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 1709939)

  • 1. Vitronectin governs the interaction between plasminogen activator inhibitor 1 and tissue-type plasminogen activator.
    Keijer J; Ehrlich HJ; Linders M; Preissner KT; Pannekoek H
    J Biol Chem; 1991 Jun; 266(16):10700-7. PubMed ID: 1709939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties.
    Ehrlich HJ; Gebbink RK; Keijer J; Linders M; Preissner KT; Pannekoek H
    J Biol Chem; 1990 Aug; 265(22):13029-35. PubMed ID: 1695900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On the target specificity of plasminogen activator inhibitor 1: the role of heparin, vitronectin, and the reactive site.
    Keijer J; Linders M; Wegman JJ; Ehrlich HJ; Mertens K; Pannekoek H
    Blood; 1991 Sep; 78(5):1254-61. PubMed ID: 1715220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
    Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
    J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The inhibition of tissue type plasminogen activator by plasminogen activator inhibitor-1. The effects of fibrinogen, heparin, vitronectin, and lipoprotein(a).
    Edelberg JM; Reilly CF; Pizzo SV
    J Biol Chem; 1991 Apr; 266(12):7488-93. PubMed ID: 1708387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The significance of fibrin binding by plasminogen activator inhibitor 1 for the mechanism of tissue-type plasminogen activator-mediated fibrinolysis.
    Stringer HA; Pannekoek H
    J Biol Chem; 1995 May; 270(19):11205-8. PubMed ID: 7744752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional interaction of plasminogen activator inhibitor type 1 (PAI-1) and heparin.
    Ehrlich HJ; Keijer J; Preissner KT; Gebbink RK; Pannekoek H
    Biochemistry; 1991 Jan; 30(4):1021-8. PubMed ID: 1703436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of tissue-type plasminogen activator-specific plasminogen activator inhibitor-1 mutants. Evidence that second sites of interaction contribute to target specificity.
    Sherman PM; Lawrence DA; Verhamme IM; Paielli D; Shore JD; Ginsburg D
    J Biol Chem; 1995 Apr; 270(16):9301-6. PubMed ID: 7721851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The interaction of plasminogen activator inhibitor 1 with plasminogen activators (tissue-type and urokinase-type) and fibrin: localization of interaction sites and physiologic relevance.
    Keijer J; Linders M; van Zonneveld AJ; Ehrlich HJ; de Boer JP; Pannekoek H
    Blood; 1991 Jul; 78(2):401-9. PubMed ID: 1712649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping of binding sites for heparin, plasminogen activator inhibitor-1, and plasminogen to vitronectin's heparin-binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin formation.
    Kost C; Stüber W; Ehrlich HJ; Pannekoek H; Preissner KT
    J Biol Chem; 1992 Jun; 267(17):12098-105. PubMed ID: 1376317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronectin in the endothelial cell matrix.
    Ehrlich HJ; Gebbink RK; Preissner KT; Keijer J; Esmon NL; Mertens K; Pannekoek H
    J Cell Biol; 1991 Dec; 115(6):1773-81. PubMed ID: 1721912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of wild-type and catalytically inactive mutant forms of tissue-type plasminogen activator with human umbilical vein endothelial cell monolayers.
    Ramakrishnan V; Sinicropi DV; Dere R; Darbonne WC; Bechtol KB; Baker JB
    J Biol Chem; 1990 Feb; 265(5):2755-62. PubMed ID: 2105933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin).
    Declerck PJ; De Mol M; Alessi MC; Baudner S; Pâques EP; Preissner KT; Müller-Berghaus G; Collen D
    J Biol Chem; 1988 Oct; 263(30):15454-61. PubMed ID: 2459123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a noninhibitory substrate for tissue-type plasminogen activator.
    Declerck PJ; De Mol M; Vaughan DE; Collen D
    J Biol Chem; 1992 Jun; 267(17):11693-6. PubMed ID: 1601844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin.
    Preissner KT; Grulich-Henn J; Ehrlich HJ; Declerck P; Justus C; Collen D; Pannekoek H; Müller-Berghaus G
    J Biol Chem; 1990 Oct; 265(30):18490-8. PubMed ID: 1698787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On the reversible interaction of plasminogen activator inhibitor-1 with tissue-type plasminogen activator and with urokinase-type plasminogen activator.
    Lijnen HR; Van Hoef B; Collen D
    J Biol Chem; 1991 Mar; 266(7):4041-4. PubMed ID: 1900284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetic analysis of the interaction between plasminogen activator inhibitor-1 and tissue-type plasminogen activator.
    Masson C; Angles-Cano E
    Biochem J; 1988 Nov; 256(1):237-44. PubMed ID: 3146972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Catabolism of tissue-type plasminogen activator by the human hepatoma cell line Hep G2. Modulation by plasminogen activator inhibitor type 1.
    Morton PA; Owensby DA; Sobel BE; Schwartz AL
    J Biol Chem; 1989 May; 264(13):7228-35. PubMed ID: 2540181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of determinants involved in binding of tissue-type plasminogen activator-plasminogen activator inhibitor type 1 complexes to HepG2 cells.
    Morton PA; Owensby DA; Wun TC; Billadello JJ; Schwartz AL
    J Biol Chem; 1990 Aug; 265(24):14093-9. PubMed ID: 2167306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of tissue-type plasminogen activator and plasminogen activator inhibitor 1 on the surface of endothelial cells.
    Sakata Y; Okada M; Noro A; Matsuda M
    J Biol Chem; 1988 Feb; 263(4):1960-9. PubMed ID: 3123483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.